Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
نویسندگان
چکیده
The supplementary data originally attached to the article cited above was incorrect. The correct version of the supplementary data has been attached to the online version of the article. Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, and Thomas A. Hardy 808 Diabetes Care Volume 40, June 2017
منابع مشابه
Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
We would like to congratulate Kazda et al. (1) for reporting the first phase 2 study of the glucagon receptor antagonist LY2409021 as a novel therapy for type 2 diabetes. This study provides further proof of efficacy of glucagon antagonism as a treatment for type 2 diabetes with acceptable adverse effects at a dose of 30 mg. However, we would like the authors to clarify certain points in the ph...
متن کاملResponse to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
We appreciate the thoughtful comments raised by Agrawal and Gupta (1) on our recent article (2) on the efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. We are pleased that they acknowledge that this study has provided further proof of efficacy of glucagon antagonism as a treatment for type 2 diabetes with acceptable adverse effects at a dose of...
متن کاملEvaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
OBJECTIVE Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS The efficacy (HbA1c and glucose) and safety (serum aminotransferase) of once-daily oral administration of...
متن کاملEfficacy and Safety of Dulaglutide Compared to Liraglutide: A Meta-analysis and Systematic Review in Patients with Type 2 Diabetes Mellitus
Introduction: Diabetes mellitus has always been one of the most prevalent chronic diseases in the last decades. There exist a wide range of pharmacological agents for controlling this disease. However, these agents fare differently in terms of efficacy and safety. Hence, the aim of this study was to compare dulaglutide and liraglutide, two glucagon-like peptide-1 receptor agonists, in terms of ...
متن کاملEfficacy and Safety of Dulaglutide Compared to Liraglutide: A Meta-analysis and Systematic Review in Patients with Type 2 Diabetes Mellitus
Introduction: Diabetes mellitus has always been one of the most prevalent chronic diseases in the last decades. There exist a wide range of pharmacological agents for controlling this disease. However, these agents fare differently in terms of efficacy and safety. Hence, the aim of this study was to compare dulaglutide and liraglutide, two glucagon-like peptide-1 receptor agonists, in terms of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Diabetes care
دوره 40 6 شماره
صفحات -
تاریخ انتشار 2017